Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465471 | 0.85 | HRH4 (0.69) | HRH4KMT2AMEN1HRH3 | |
| SCHEMBL22615126 | 0.85 | HRH4 (0.69) | HRH4KMT2AMEN1HRH3 | |
| SCHEMBL2351433 | 0.83 | HRH4 (0.78) | HRH4MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL6382929 | 0.83 | KMT2A (0.73) | HRH4KMT2AMEN1RAB9AHRH3 | |
| SCHEMBL3539385 | 0.83 | KMT2A (0.51) | HRH4KMT2AMEN1NPC1RAB9A | |
| SCHEMBL23441333 | 0.83 | HRH4 (0.50) | HRH4KMT2AMEN1NPC1RAB9A | |
| SCHEMBL3166069 | 0.83 | KMT2A (0.53) | HRH4MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL3541555 | 0.83 | HRH3 (0.53) | HRH4KMT2AMEN1NPC1RAB9A | |
| SCHEMBL3169524 | 0.83 | KMT2A (0.66) | HRH4KMT2AMEN1NPC1RAB9A | |
| SCHEMBL2347252 | 0.82 | HRH4 (0.76) | HRH4MAPTKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470691-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | ABBVIE INC. | 2007-11-15 | — | — | US | disclosed |
| US-7235661-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-7057042-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | WEINSTOCK, STEVEN F. | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063713-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | HRH4 812/4885MAPT 2852/4885KDM4E 3657/4885 |
| US-20070265249-A1 | Fused Bicyclic Aromatic Compounds that are Useful in Treating Sexual Dysfunction | CYP19A1, CYP17A1, HSD17B11 | HRH4 555/4885MAPT 2666/4885KDM4E 2778/4885 |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, DDC | HRH4 639/4885MAPT 2685/4885KDM4E 2026/4885 |
| US-20040002488-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, HSD17B11 | HRH4 812/4885MAPT 2852/4885KDM4E 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.